AstraZeneca: FDA approves application for Enhertu

(CercleFinance.com) - AstraZeneca announces that the supplemental Biologics License Application (sBLA) for Enhertu has been accepted with priority review by the FDA to treat HER2-low or HER2-ultralow unresectable or metastatic breast cancer.


Based on the positive results of the DESTINY-Breast06 trial, this review could enable Enhertu to be marketed as early as 2025.

Enhertu demonstrated a 37% reduction in the risk of disease progression compared to chemotherapy.

The FDA has also granted Enhertu Breakthrough Therapy designation, underlining its potential for wider and earlier use.

Copyright (c) 2024 CercleFinance.com. All rights reserved.